Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × lorlatinib × Tumor-Agnostic × Clear all

Phase

Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Tumor-Agnostic 1 CNS 1

Conditions

Interventions

Drug Therapy 5 Docetaxel 3 Bevacizumab 3 icotinib 2 Pemetrexed 2 Misoprostol 2 Genes, p53 2 Gemcitabine 2 Dexamethasone 2 Carboplatin 2 Aspirin 2 pinaverium 1 pentetreotide 1 pembrolizumab 1 pazopanib 1 netupitant, palosentron drug combination 1 nedaplatin 1 lorlatinib 1 durvalumab 1 ceritinib 1 atezolizumab 1 Zoledronic Acid 1 Water 1 Vitamin E 1 Vincristine 1 Vemurafenib 1 Ultracet 1 Triamcinolone 1 Trastuzumab 1 Thalidomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04362072 2025-06-11

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Pfizer

Phase 4 Completed

71 enrolled 26 charts

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡